The COVID-19 pandemic is a rapidly evolving global crisis and there
is much that is still emerging in terms of the psychosocial and mental
health consequences for the diverse populations affected by this
emergency. This toolkit is based on what is currently available and
will be updated as addit...ional resources become available.
more
There is no secret to our procedure: the daily scanning of the literature helps us to stay afloat in the never-ending waves of new publications about SARS-CoV-2 and COVID-19. Many papers discussed in the Top 10 will eventually make it into subsequent editions of COVID Reference.
DOI:https://doi.org/10.1016/S2213-2600(20)30316-7
The Lancet Respiratory Medicine
Every day – Monday, Tuesday, Wednesday, Thursday, Friday, Saturday, Sunday – they present the Top 10 scientific COVID-19 papers of the day. The daily scanning of the literature helps us to stay afloat in the never-ending waves of new publications about SARS-CoV-2 and COVID-19
There is no secret to our procedure: the daily scanning of the literature helps us to stay afloat in the never-ending waves of new publications about SARS-CoV-2 and COVID-19. Many papers discussed in the Top 10 will eventually make it into subsequent editions of COVID Reference.
В кратких клинических рекомендациях представлен перечень наиболее актуальных сведений о новой коронавирусной инфекции COVID-19. Он разработан рабочей группой, созда...нной при губернаторе Санкт-Петербурга, в состав которой вошли эксперты — акушеры-гинекологи, анестезиологи-реаниматологи, клинические фармакологи, кардиологи, организаторы здравоохранения, в качестве информационного ресурса для специалистов, работающих в сфере охраны материнства и детства.
Краткие клинические рекомендации предназначены врачам — акушерам-гинекологам, анестезиологам-реаниматологам, врачам скорой медицинской помощи и другим специалистам, работающим в области оказания медицинской помощи беременным, роженицам и родильницам в Санкт-Петербурге и Северо-Западном федеральном округе, а также клиническим ординаторам.
more
The Platform has functionality for country-level users, such as uploading theNational Deployment and Vaccination Planon the Info tab by the WCO vaccine expert, followed by validation by a government official. The Platform has functionality for regional users, such as Reviewingof National Deployment ...and Vaccination Plan(NDVP) on the Action Checklist tabor uploading a summary of the review of the NDVP on the Info tab and within the NDVP folder.
more
8 February 2021
This document highlights 10 well established Risk Communication and Community Engagement (RCCE) principles that have proven their power. Together they put communities at the heart of the roll out of new vaccines, treatments and tests and promote trust, the critical ingredient for al...l community action. Informed, engaged and empowered communities are the bedrock for the arrival of new vaccines, treatments and tests that will be introduced to reduce the spread of COVID-19 and save lives. With communities fully engaged and actively participating through the full cycle of planning, delivery and assessment for biomedical tools, demand for these tools can be increased, leading to widespread and effective uptake and use
more
10 BAGAY OU K A FÈ POU JERE SENTÒM
COVID-19 OU YO L AK AY OU
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Stand 21. Dezember 2021
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Natural immunity against COVID-19
Scientific report 10 May 2021
COVID-19 Situation Update OPS/WHO Argentina: 10 February 2022
Situation report generated by the OPS/WHO representation in Argentina
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more